New combo attack on lung cancer in the brain
NCT ID NCT07413952
Summary
This study is testing whether a new targeted drug called limertinib works better when combined with radiation therapy for people with a specific type of lung cancer (EGFR-mutant) that has spread to the brain. It will involve about 45 adults who have not yet received any treatment for their advanced cancer. The main goal is to see how long the treatment can control the cancer in the brain and to check its safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong
Guangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.